Table 1.
Participant characteristics.
| Biotype 1 (N = 36) | Biotype 2 (N = 24) | Biotype 3 (N = 20) | Controls (N = 80) | Stat | p- value | |
|---|---|---|---|---|---|---|
| Age in years mean (SD) | 49.30 (8.0) | 52.52 (6.4) | 52.16 (8.7) | 49.29 (13.2) | F = 0.802 | 0.494 |
| Education in years mean (SD) | 16.39 (2.4) | 17.13 (2.7) | 16.47 (2.2) | 16.99 (2.4) | F = 0.782 | 0.506 |
| Racial/ethnic minority (%) | 36% | 13% | 12% | 16% | X2 = 8.70 | 0.033 |
| Post-menopause (%) | 61% | 71% | 59% | 67% | X2 = 1.09 | 0.779 |
| Stage at diagnosis (I, II, III %) | 30,65,5% | 21,41,38% | 18,65,17% | X2 = 5.42 | 0.247 | |
| Radiotherapy (%) | 67% | 96% | 65% | X2 = 7.91 | 0.019 | |
| Hormone blockade (%) | 61% | 75% | 64% | X2 = 1.27 | 0.531 | |
| Months since primary therapy* ended (SD) | 26.40 (18.7) | 49.67 (33.9) | 64.25 (82.1) | F = 4.69 | 0.012 |
SD, standard deviation. *Surgery, radiation, chemotherapy.